Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094550 | 0.90 | CCR2 (0.40) | CCR2TSHR | |
| SCHEMBL10137697 | 0.81 | CCR2 (0.38) | MEN1LMNAKMT2ACCR2SCN9A | |
| SCHEMBL10137699 | 0.76 | CCR2 (0.48) | MEN1LMNAKMT2ACCR2MAPT | |
| SCHEMBL1095250 | 0.70 | CCR2 (0.40) | CCR2TSHR | |
| SCHEMBL10137693 | 0.69 | CCR2 (0.48) | MEN1LMNAKMT2ACCR2MAPT | |
| SCHEMBL1094311 | 0.69 | HSD17B2 (0.45) | CCR2 | |
| SCHEMBL1094134 | 0.68 | CCR2 (0.52) | CCR2 | |
| SCHEMBL1094196 | 0.63 | CCR9 (0.54) | — | |
| SCHEMBL1093876 | 0.62 | HSD17B2 (0.43) | MEN1KMT2ACCR2MAPTALDH1A1 | |
| SCHEMBL3533098 | 0.62 | CYP2C9 (0.47) | CCR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481579-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120165303-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165303-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | MEN1 4877/4885LMNA 4279/4885KMT2A 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.